evidencegaps
Primary study · included by 1 review

The efficacy and safety of 225Ac-PSMA-617 in metastatic castration-resistant prostate cancer.

Ma 2025 · Ma Jiao, Zhang Yu, Yangqing Jiangchu, et al. · Frontiers in oncology · 2025

Included by

Beyond [177Lu]Lu-PSMA: a meta-analysis of safety and efficacy of emerging PSMA radioligand therapy agents.
Non-Cochrane · intervention · 2026 · cited as Ma 2025 · Reference list refs 21-53; Table 2; Supplementary Table 5

The review does not say which of its outcomes this study informs.

1 including review in total.